Xeloda Dosage Calculator
This tool calculates the recommended daily dose of Xeloda (capecitabine) based on body surface area (BSA) for colorectal and breast cancer treatments.
Xeloda is a oral fluoropyrimidine pro‑drug that is metabolically converted to 5‑fluorouracil (5‑FU) after ingestion. Marketed under the generic name capecitabine, it was approved in 1998 and quickly became a staple for metastatic colorectal and breast cancers because patients can take it at home instead of getting intravenous infusions.
How Xeloda Works Inside the Body
After swallowing a capsule, capecitabine travels through the bloodstream to the liver, where the enzyme carboxylesterase turns it into 5′‑deoxy‑5‑fluorocytidine (5′‑DFCR). A second enzyme, cytidine deaminase, converts 5′‑DFCR into 5′‑deoxy‑5‑fluorouridine (5′‑DFUR). The final step occurs preferentially inside tumour cells: thymidine phosphorylase (TP) - an enzyme over‑expressed in many cancers - transforms 5′‑DFUR into the active chemotherapeutic 5‑FU.
Because TP is abundant in tumour tissue but scarce in most normal organs, Xeloda delivers higher concentrations of 5‑FU right where it’s needed, sparing healthy cells and reducing systemic toxicity.
Approved Clinical Indications
Capecitabine is officially indicated for:
- Adjuvant treatment of stage III colon cancer (often combined with oxaliplatin as the XELOX regimen).
- Metastatic colorectal cancer, either as monotherapy or combined with biologics such as bevacizumab.
- Metastatic breast cancer, especially in patients who have progressed after anthracycline‑ and taxane‑based regimens.
Real‑world data from the United Kingdom’s National Cancer Registry show that more than 40,000 patients received capecitabine between 2015‑2022, with median overall survival of 22 months in metastatic colorectal settings.
Typical Dosing and Administration
Standard dosing follows a 2‑weeks‑on, 1‑week‑off cycle:
- Colorectal cancer: 1250mg/m² taken twice daily (approximately 12hours apart) for 14 days.
- Breast cancer: 1000mg/m² twice daily for 14 days.
- Dose reductions are common for renal impairment (creatinine clearance <50mL/min) - typically a 25‑30% cut‑back.
Patients are instructed to swallow tablets whole with water and avoid food for at least an hour after taking each dose to improve absorption.
Common Side‑Effects and Safety Profile
Because Xeloda delivers 5‑FU systemically, its toxicity mirrors that of intravenous fluoropyrimidines, but oral administration introduces a few unique concerns:
- Hand‑foot syndrome - redness, swelling, and painful peeling of the palms and soles; occurs in up to 30% of users.
- Diarrhoea - can be severe; patients should stay hydrated and report watery stools promptly.
- Myelosuppression - neutropenia and thrombocytopenia are less frequent than with IV 5‑FU but still require CBC monitoring.
- Cardiotoxicity - rare but notable; chest pain or palpitations warrant immediate evaluation.
Pharmacogenomic testing for DPYD gene variants (which affect 5‑FU catabolism) is now recommended before initiating capecitabine, as deficient patients face a dramatically higher risk of life‑threatening toxicity.
Xeloda alternatives: Major Chemotherapy Options to Consider
When clinicians discuss "Xeloda alternatives," they usually refer to other fluoropyrimidine‑based regimens or drugs that achieve similar anti‑DNA synthesis effects. Below are the most frequently considered options, each defined with microdata for clarity.
5‑Fluorouracil (IV) is a synthetic pyrimidine analogue administered intravenously, directly delivering 5‑FU into the bloodstream.
Tegafur/Uracil (UFT) combines the pro‑drug tegafur (a 5‑FU precursor) with uracil, a competitive inhibitor of dihydropyrimidine dehydrogenase, to sustain systemic 5‑FU levels.
S‑1 is a Japanese‑origin oral formulation that mixes tegafur with two modulators - gimeracil (DPD inhibitor) and oteracil (reduces gastrointestinal toxicity).
Trifluridine/Tipiracil (Lonsurf) is a combination of a nucleoside analogue (trifluridine) and a thymidine phosphorylase inhibitor (tipiracil) approved for treatment‑refractory metastatic colorectal cancer.
Side‑by‑Side Comparison Table
| Drug | Route | Typical Indication | Dosing Schedule | Principal Side‑Effects |
|---|---|---|---|---|
| Xeloda | Oral | Metastatic/Adjuvant colorectal & breast cancer | 2 weeks on, 1 week off (twice‑daily) | Hand‑foot syndrome, diarrhoea, myelosuppression |
| 5‑Fluorouracil (IV) | Intravenous | Colorectal, gastric, head‑and‑neck cancers | Bolus or continuous 48‑h infusion weekly | Mucositis, neutropenia, cardiotoxicity |
| UFT | Oral | Colorectal, gastric cancer (often with leucovorin) | 3 tablets three times daily for 14 days, 7‑day break | Gastro‑intestinal upset, rash |
| S‑1 | Oral | Gastric, pancreatic, colorectal cancers (Asia‑centric practice) | 2 weeks on, 1 week off (twice‑daily) | Neutropenia, nausea, fatigue |
| Trifluridine/Tipiracil (Lonsurf) | Oral | Refractory metastatic colorectal cancer | Day 1‑5 and 8‑12 of a 28‑day cycle | Neutropenia, anaemia, diarrhoea |
Decision‑Making Criteria: When to Choose Xeloda vs an Alternative
Clinicians weigh several factors before selecting a regimen:
- Patient convenience - oral drugs (Xeloda, UFT, S‑1, Lonsurf) avoid frequent clinic visits.
- Renal and hepatic function - capecitabine requires dose adjustment for renal impairment; IV 5‑FU is safer for low creatinine clearance.
- DPYD status - patients with deficient DPYD may tolerate S‑1 better because gimeracil blocks DPYD activity.
- Previous exposure - if a patient progressed on IV 5‑FU, switching to an oral pro‑drug like Xeloda can provide a fresh pharmacokinetic profile.
- Side‑effect tolerance - hand‑foot syndrome is unique to capecitabine; those who develop severe cases might be shifted to IV 5‑FU or Lonsurf.
Practical Tips for Managing Xeloda Therapy
- Start with a full DPYD genotype test; dose‑reduce if a variant is present.
- Educate patients on the importance of taking the drug with water on an empty stomach - food can lower bioavailability by up to 30%.
- Schedule CBC and liver function tests every two weeks for the first two cycles, then monthly.
- Offer moisturising creams and avoid tight shoes at the first sign of hand‑foot redness; early intervention reduces severity.
- Keep a medication diary - adherence drops if patients miss doses on weekends; a simple checklist improves compliance by 15%.
Related Concepts and Connected Topics
Understanding Xeloda’s place in modern oncology often leads to deeper exploration of the following areas:
- DPYD pharmacogenetics - how genetic variants affect 5‑FU metabolism and guide dose adjustments.
- Oral chemotherapy adherence - strategies to monitor and improve patient compliance.
- Combination regimens - pairing Xeloda with oxaliplatin (XELOX) or bevacizumab for synergistic effect.
- Hand‑foot syndrome management - evidence‑based topical treatments and dose‑modification algorithms.
- Real‑world effectiveness studies - population‑based data on survival and quality of life.
Readers who want to dive deeper can explore each bullet point as a stand‑alone article, building a comprehensive knowledge network around fluoropyrimidine therapy.
Frequently Asked Questions
Is Xeloda as effective as IV 5‑FU for colorectal cancer?
Large phase III trials (e.g., the NO16966 study) showed that capecitabine provides comparable overall survival to IV 5‑FU while offering the convenience of oral dosing. In some sub‑analyses, capecitabine even showed a modest improvement in progression‑free survival for specific biomarker‑defined groups.
Can I take Xeloda if I have kidney problems?
Renal function is a key consideration. Patients with a creatinine clearance below 30mL/min are generally not recommended for capecitabine. Those in the 30‑50mL/min range should receive a 25‑30% dose reduction and close monitoring of toxicities.
What is hand‑foot syndrome and how do I prevent it?
Hand‑foot syndrome (palmar‑plantar erythrodysthesia) manifests as redness, swelling, and painful peeling on the palms and soles. Preventive measures include using urea‑based moisturisers, wearing loose‑fitting shoes, and reducing the dose at the first sign of symptoms. Early topical steroid use can also curb severity.
How does S‑1 differ from Xeloda?
S‑1 combines tegafur with two modulators: gimeracil (inhibits DPYD, raising 5‑FU levels) and oteracil (limits gastrointestinal exposure). This design reduces GI toxicity and can be safer for patients with DPYD deficiency, whereas Xeloda relies on tumour‑specific TP activation and may cause more hand‑foot reactions.
When is Trifluridine/Tipiracil (Lonsurf) preferred over Xeloda?
Lonsurf is approved for patients with metastatic colorectal cancer who have exhausted standard fluoropyrimidine, oxaliplatin, and irinotecan options. Its distinct mechanism (trifluridine incorporation into DNA) offers activity when tumours become resistant to 5‑FU‑based drugs, making it a later‑line choice rather than a first‑line substitute for Xeloda.
Written by Mallory Blackburn
View all posts by: Mallory Blackburn